BESPOKE Study of ctDNA Guided Immunotherapy

Prospective Inclusion Criteria: 1. Male or female patients 18 years of age or older at the time of signing informed consent form (ICF) 2. Any patient with documented metastatic or locally advanced, unresectable cancer of the types within the following cohorts: 1. Melanoma 2. Non-small cell lung cancer 3. Colorectal cancer 3. Patients must be clinically eligible and planned to receive therapy with an anti-neoplastic agent that works by immune checkpoint blockade, anti-PD-1, anti-CTLA-4, or anti-PD-L1: 1. Pembrolizumab (Keytruda) 2. Nivolumab (Opdivo) 3. Ipilimumab (Yervoy) 4. Durvalumab (Imfinzi) 5. Cemiplimab (Libtayo) 6. Atezolizumab (Tecentriq) 7. Avelumab (Bavencio) 4. Patients must have measurable disease according to RECIST criteria, and at least one lesion that can be accurately measured in at least one dimension as \>10 mm. 5. Patients must be able to follow study visit schedule and willing to provide up to 20 mL of peripheral blood samples at the indicated time points 6. ECOG Performance status 0,1, or 2 7. Able to read, understand and provide written informed consent 8. Willing and able to comply with the study requirements 9. Selected by their HCP to receive SIGNATERA testing according to the current evidence-informed schedule as part of their routine of practice Prospective Exclusion Criteria: 1. Female patients that are pregnant 2. History of bone marrow or organ transplant 3. Medical condition that would place the patient at risk as a result of blood donation, such as bleeding disorder 4. Serious medical condition that may adversely affect ability to participate in the study 5. Has initiated Immunotherapy Control Arm Inclusion Criteria: 1. Male or female patients 18 years of age or older at the time of signing informed consent form (ICF) 2. Any patient with documented metastatic or locally advanced, unresectable cancer of the types within the following cohorts: 1. Melanoma 2. Non-small cell lung cancer 3. Colorectal cancer 3. Patients must be clinically eligible and planned to receive therapy with an anti-neoplastic agent that works by immune checkpoint blockade, anti-PD-1, anti-CTLA-4, or anti-PD-L1: 1. Pembrolizumab (Keytruda) 2. Nivolumab (Opdivo) 3. Ipilimumab (Yervoy) 4. Durvalumab (Imfinzi) 5. Cemiplimab (Libtayo) 6. Atezolizumab (Tecentriq) 7. Avelumab (Bavencio) 4. Patients must have measurable disease according to RECIST criteria, and at least one lesion that can be accurately measured in at least one dimension as \>10 mm. 5. Patients must be able to follow study visit schedule and willing to provide up to 20 mL of peripheral blood samples at the indicated time points 6. ECOG Performance status 0,1, or 2 7. Able to read, understand and provide written informed consent 8. Willing and able to comply with the study requirements 9. Selected by their HCP to receive SIGNATERA testing according to the current evidence-informed schedule as part of their routine of practice Control Arm Exclusion Criteria: 1. Female patients that are pregnant 2. History of bone marrow or organ transplant 3. Medical condition that would place the patient at risk as a result of blood donation, such as bleeding disorder 4. Serious medical condition that may adversely affect ability to participate in the study 5. Has initiated Immunotherapy